EUVIMEDEUVIMED entdecken
Crossref

Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma

Sitah Alharthi, Seyed Zeinab Alavi, Mehr Un Nisa, Maedeh Koohi, Aun Raza, Hasan Ebrahimi Shahmabadi, Seyed Ebrahim Alavi

Pharmaceutical Research · 2024

DOI: 10.1007/s11095-024-03722-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Sitah Alharthi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi, 11961, Saudi Arabia. Hauptthemen laut MEDLINE: Dendritic Cells, Mice, Inbred C57BL, Polyethylene Glycols, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aims to utilize PEGylated poly (lactic-co-glycolic acid) (PLGA) nanoparticles as a delivery system for simultaneous administration of the BRAFV600E peptide, a tumor-specific antigen, and imiquimod (IMQ). The objective is to stimulate dendritic cell (DC) maturation, activate macrophages, and facilitate antigen presentation in C57BL6 mice. METHODS: PEG-PLGA-IMQ-BRAFV600E nanoparticles were synthesized using a PLGA-PEG-PLGA tri-block copolymer, BRAFV600E, and IMQ. Characterization included size measurement and drug release profiling. Efficacy was assessed in inhibiting BPD6 melanoma cell growth and activating immature bone marrow DCs, T cells, macrophages, and splenocyte cells through MTT and ELISA assays. In vivo, therapeutic and immunogenic effects potential was evaluated, comparing it to IMQ + BRAFV600E and PLGA-IMQ-BRAFV600E nanoparticles in inhibiting subcutaneous BPD6 tumor growth. RESULTS: The results highlight the successful synthesis of PEG-PLGA-IMQ-BRAFV600E nanoparticles (203 ± 11.1 nm), releasing 73.4% and 63.2% of IMQ and BARFV600E, respectively, within the initial 48 h. In vitro, these nanoparticles demonstrated a 1.3-fold increase in potency against BPD6 cells, achieving ~ 2.8-fold enhanced cytotoxicity compared to PLGA-IMQ-BRAFV600E. Moreover, PEG-PLGA-IMQ-BRAFV600E exhibited a 1.3-fold increase in potency for enhancing IMQ cytotoxic effects and a 1.1- to ~ 2.4-fold increase in activating DCs, T cells, macrophages, and splenocyte cells compared to IMQ-BRAFV600E and PLGA-IMQ-BRAFV600E. In vivo, PEG-PLGA-IMQ-BRAFV600E displayed a 1.3- to 7.5-fold increase in potency for inhibiting subcutaneous BPD6 tumor growth compared to the other formulations. CONCLUSIONS: The findings suggest that PEG-PLGA nanoparticles effectively promote DC maturation, T cell activation, and potentially macrophage activation. The study highlights the promising role of this nanocomposite in vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsMice, Inbred C57BLPolyethylene GlycolsProto-Oncogene Proteins B-rafMelanomaNanoparticlesImiquimodAnimalsCell Line, TumorMiceAdjuvants, ImmunologicFemalePolylactic Acid-Polyglycolic Acid CopolymerMacrophagesDrug LiberationHumansSkin Neoplasms

Stichwörter der Autor:innen

BRAF-mutant melanomaPEG-PLGAcancernanoparticlesvaccines

Substanzen

Polyethylene GlycolsProto-Oncogene Proteins B-rafImiquimodAdjuvants, ImmunologicPolylactic Acid-Polyglycolic Acid Copolymer

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi, 11961, Saudi Arabia.
  • Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran.
  • Nishtar Medical University and Hospital, Multan, 60000, Pakistan.
  • School of Pharmacy, Fudan University, Shanghai, 201203, PR China.
  • Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran. ebrahimi@rums.ac.ir.
  • Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, 7718175911, Iran. s.ebrahimalavi@gmail.com.

Zitieren

APA

Alharthi, S., Alavi, S. Z., Nisa, M. U., Koohi, M., Raza, A., Ebrahimi Shahmabadi, H., & Alavi, S. E. (2024). Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03722-1

Vancouver

Alharthi S, Alavi SZ, Nisa MU, Koohi M, Raza A, Ebrahimi Shahmabadi H, et al. Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03722-1

BibTeX
@article{Alharthi2024,
  author = {Alharthi, Sitah and Alavi, Seyed Zeinab and Nisa, Mehr Un and Koohi, Maedeh and Raza, Aun and Ebrahimi Shahmabadi, Hasan and Alavi, Seyed Ebrahim},
  title = {Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma},
  journal = {Pharmaceutical Research},
  year = {2024},
  doi = {10.1007/s11095-024-03722-1}
}
Kostenlos starten →